PRINCETON, NJ, December 23, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings (NASDAQ:), Inc. (the Firm or Sonnet) (NASDAQ: SONN), a clinical-stage firm growing focused immunotherapeutic medicine, right this moment introduced that the subsequent CEO Nook section has been launched on the Firm web site.
As a part of the CEO Nook section, Pankaj Mohan, Ph.D., founder and CEO of Sonnet, highlighted the corporate’s key achievements for calendar yr 2024 and focused worth creation milestones throughout the yr calendar 2025.
The CEO Nook is now accessible on the Firm’s web site right here. Segments of the CEO Nook platform might be accessible on the Firm’s web site (www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology firm with a proprietary platform for single- and bifunctional-acting biologic drug innovation. Often known as FHAB (Absolutely Human Albumin Binding), the know-how makes use of a completely human single-chain antibody fragment (scFv) that binds to human serum albumin (HSA) and “hitchhikes” for transport to focus on tissues. The F in SonnetHAB was designed to particularly goal tumors and lymphatic tissues, with an improved therapeutic window to optimize the protection and efficacy of immunomodulatory biologics. FHAB is the premise for a ready-to-use modular assemble to potentiate a variety of huge molecule therapeutic courses, together with cytokines, peptides, antibodies and vaccines.
Investor Relations Contact:
JTC Workforce, LLC
Jénène Thomas
908.824.0775
SONN@jtcir.com
#Sonnet #BioTherapeutics #Pronounces #Upcoming #CEO #Nook #Phase #Investing.com , #Gossip247
,
